IMI 10th Anniversary Scientific Symposium

Agenda
Day 1
22.10.18

22.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00	Registration & welcome coffee

09:00 – 10:00	Opening session

Pierre Meulien, Executive Director, IMI
Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee, UCB
Jonathan Knowles, Professor, Founding Chairman of IMI Board

10:00 – 11:00	Stratification towards personalised medicines

10:00 – 10:15   Setting the scene
- Pierre Meulien, Executive Director, IMI

10:15 – 11:00   Presentation of key achievements from IMI projects
- *"Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer's Disease and Reconstruction of Relevant Mechanisms"*
  AETIONOMY - Holger Fröhlich, UCB

- *"Quantitative PET Imaging - From Research to Clinical Use"*
  AMYPAD - Fiona Heeman, VU University medical centre

- *"Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium"*
  DIRECT - Robert Koivula, University of Oxford

11:00 – 11:30	Coffee break

11:30 – 12:15   Presentation of key achievements from IMI projects
- *"Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study"*
  EPAD - Silvia Ingala, VU Medical Center

- *"The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery"*
  EU-AIMS - Stefan Holiga, F. Hoffmann-La Roche & Eva Loth, King's College London

- *"Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain"*
  EUROPAIN - Jan Vollert, Imperial College London

- *"Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors"*
  Onco Track - Moritz Schütte, Alacris Theranostics GmbH

- *"Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression"*
  PRECISESADS - Daniel Toro, GENYO

12:15 – 13:30	**Lunch**

13:30 – 14:00   Presentation of key achievements from IMI projects
- *"Federating clinical data for biomedical research in type 2 diabetes"*
  RHAPSODY - Thomas Sparsø, Novo Nordisk

- *"Building handprints of complex diseases – severe asthma as a proof of concept"*
  U-BIOPRED and eTRIKS - Bertrand De Meulder, European Institute for Systems Biology and Medicine

14:00 – 14:30   Panel discussion:
- Pamela Tenaerts, Executive Director, Clinical Trial Transformation Initiative
- Raj Long, Deputy Director - Integrated Development, Global Health, Bill & Melinda Gates Foundation
- Martin Hofmann-Apitius, Head of the Department of Bioinformatics, Fraunhofer SCAI
- Maria Beatriz Da Silva Lima, Professor of Pharmacology and Pharmacotoxicology, Lisbon University

14:30 – 15:00	**Coffee break**

15:00 – 17:15	**Patient centric approaches in drug development**

15:00 – 15:15   Setting the scene
- Virginie Hivert, Therapeutic Development Director, EURORDIS

15:15 – 16:45   Presentation of key achievements from IMI projects
- *"Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients"*
  APPROACH - Leonie Hussaarts, Lygature & Jane Taylor

- *"Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines"*
  EUPATI - Tamàs Bereczky, Eupati

- *"Driving the use of Real World Evidence in healthcare decision making"*
  GETREAL - Amr Makady, Zorginstituut Nederland

- *"When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations"*
  PREFER - Chiara Whichello and Eline van Overbeeke, KU Leuven

- *"From development to labelling claim"*
  PRO-active - Heleen Demeyer, Uz Gasthuisberg

- *"Baseline characteristics of participants of the SPRINTT randomised clinical trial"*
  SPRINTT - Riccardo Calvani, Università Cattolica del Sacro Cuore

16:45 – 17:15   Panel discussion:
- Virginie Hivert, Therapeutic Development Director, EURORDIS
- Mary Baker, President, European Brain Council
- Fernand Sauer, Member, Académie National de Pharmacie
- Olivier Arnaud, Senior Director, European Research JDRF

17:15 – 19:15	Poster session

18:00 – 22:00	Networking cocktail

Agenda
Day 2
23.10.18

23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00   Registration & welcome coffee

09:00 – 09:15	Introduction

09:00 – 09:15   Pierre Meulien, Executive Director, IMI

09:15 – 11:15	Enablers for discovery and development of new drugs

09:15 – 09:30   Setting the scene
- Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen

09:30 – 11:15   Presentation of key achievements from IMI projects
- *"An iPSC technology development collaboration – a critical component to enable ADAPTED"*
  ADAPTED - Peter Reinhardt, AbbVie & Benjamin Schmid, Bioneer

- *"Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets"*
  COMPACT - Thanki Kaushik, University of Copenhagen

- *"Supporting stem cell research with modern data management technologies"*
  EBISC - Stefanie Seltmann, Charité Berlin

- *"EMIF Catalogue – the bridge between data custodians and biomedical researchers"*
  EMIF - Alina Trifan, University of Aveiro

- *"HARMONY Platform: using Big Data to fight blood cancers"*
  HARMONY - Maria Abáigar-Alvarado, Institute of Biomedical Research of Salamanca

- *"Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavaibility: case example with posaconazole"*
  ORBITO - Bart Hens, KU Leuven

- *"Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol"*
  RADAR-CNS - Faith Matcham, King's College London

11:15 – 11:45	Coffee break

11:45 – 12:15   Panel discussion:
- Jan Egebjerg, Senior Director, Neurodegeneration Discovery Biology, Janssen
- Stefan Jaroch, Head External Innovation Technologies, R&D Pharmaceuticals, Bayer AG
- Magali Haas, CEO & President, Cohen Veterans Bioscience
- Heiko Zimmermann, Head of Institute, Fraunhofer-Institut für Biomedizinische Technik IBMT
- Hans-Georg Eichler, Senior medical officer, European Medicines Agency

12:15 – 13:30	Lunch

13:30 – 15:30	Collaborating to fight infections

13:30 – 13:45   Setting the scene
- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline

13:45 – 15:00   Presentation of key achievements from IMI projects
- *"EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriacea (CRE) along Europe. Inside COMBACTE network; global information for a global problem"* **COMBACTE-CARE - Maria Paniagua, Hospital Universitario Virgen Macarena**

- *"A new European network for influenza vaccine effectiveness studies"* **DRIVE - Topi Turunen, FISABIO**

- *"Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone"* **EbolaMoDRAD - Colavita Francesca, INMI**

- *"Modelling the humoral immune response to Ebola vaccine"* **EBOVAC1 - Irene Balelli, Inserm**

- *"Highly potent heavy chain only antibodies protect against MERS-CoV infection"* **ZAPI - Nisreen Okba, Erasmus Medical Center**

15:00 – 15:30   Panel discussion:
- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline
- Raj Long, Deputy Director - Integrated Development, Global Health, Bill & Melinda Gates Foundation
- Seamus O'Brien, R&D Director, Global Antibiotic Research and Development Partnership (GARDP)
- Isabelle Bekeredjian-Ding, Head of the Department of Microbiology, Paul-Ehrlich-Institut

15:30 – 16:00	Coffee break

16:00 – 17:00	Closing & Prize ceremony

Poster Session

22 & 23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

New targets, tools and pathways

1. *"Support Translation Research with High Quality Data and Interactive Visual-analytics"*
   eTRIKS - Kavita Rege, University of Luxembourg

2. "*Developing a robust evidence base on RSV disease and economic burden using a multi-disciplinary approach"*
   RESCEU - Rachel Reeves, the University of Edinburgh

3. *"AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design"*
   AMYPAD - Daniele Altomare, IRCCS Fatebenefratelli

4. *"Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data"*
   TransQST - Emre Guney , GRIB - IMIM / UPF

5. *"Stroke Risk, Bleeding Risk and Anticoagulation in Hospital EHRs"*
   Big data @ heart - Daniel Bean, King's College London & HDR UK

6. *"DPP6 as a new biomarker suitable for human islet in vivo imaging"*
   INNODIA - Stéphane Demine, ULB Center for Diabetes Research

7. *"Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology"*
   PRISM - Niels Jongs , Rijksuniversiteit Groningen

8. *"Drug Evaluation in Guinea Pig Model"*
   PreDiCT TB - Faye Lanni, Public Health England

9. *"The APPROACH Consortium: a 2-year, European, cohort study to describe, validate, and predict phenotypes of knee osteoarthritis using clinical, imaging, and biochemical markers"*
   APPROACH - Eefje Van Helvoort, University Medical Centre Utrecht

10. *"In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety"*
    TRISTAN - Irma Mahmutovic Persson, Lund University

11. *"RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers"*
   **ITCC-P4 - Natalie Jäger, DKFZ and KiTZ, Heidelberg**

12. *"Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours"*
ITCC-P4 - Sebastian Brabetz, Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ)

13. *"Candidate genes and pathways from ADAPTED Stage I integrative analysis"*
ADAPTED - Laura Madrid Márquez, CAEBi Bioinformatica

14. *"Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study"*
EMIF-AD - Isabelle Bos , Maastricht University

15. *"Data analytics and bioinformatics to successfully define asthma subphenotypes"*
U-BIOPRED - Stelios Pavlidis, Data Science Institute, Imperial College London

16. *"Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist"*
K4DD - Tale Sliedrecht, Lygature

17. *"Developing a mechanism-based taxonomy of Alzheimer's and Parkinson's disease"*
AETIONOMY - Sepehr Golriz Khatami, Fraunhofer SCAI

18. *"Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis"*
OncoTrack - Alireza Azimi, Uppsala University

19. *"Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling"*
NGN-PET - Lucia Rutigliano, Axxam

20. *"A new way to monitor Multiple Sclerosis"*
RADAR-CNS - Matteo Martinis, San Raffaele Hospital

21. *"Discovery of the role of the ELOVL2/docosahexaenoic acid axis in the regulation of insulin secretion and survival of rodent and human pancreatic beta cells"*
IMIDIA - Lara Bellini, Université Paris Diderot

22. *"Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study"*
DIRECT - Francesca Frau, Sanofi

23. *"Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity"*
VAC2VAC - Marilena Paola Etna, Instituto Superiore di Sanità

24. *"Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues"*
ZAPI - Paul Wichgers Schreur, Wageningen Bioveterinary Research

25. *"Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa"*
COMBACTE-MAGNET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges

26. *"Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin"*
COMBACTE-NET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges

27. *"Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia"*
RAPP-ID - Bart Jongers, University of Antwerp

28. *"Laboratory Analysis workflows within the ASPIRE-ICU study"*
COMBACTE-NET and COMBACTE-MAGNET - Leen Timbermont, University of Antwerp

29. *"New bio-informatic approach for the analysis of flow cytometry data"*
PRECISESADS - Lucas Le Lann, University of Brest

30. *"Zebrafish Proteinopathy Models for Target Validation"*
IMPRiND - Jeffrey Hubbard, Institut de Recherches Servier

31. *"New candidate genes in insulin target tissues: Elovl2 as a protective enzyme against glycaemic deterioration?"*
RHAPSODY - Justine Lallement, Université Paris Diderot

32. *"Integration of models of drug-induced liver injury for risk assessment"*
Trans-QST and MIP-DILI - Rowena Sison-Young, University of Liverpool

33. *"Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development"*
ELF - Pravin Patil, University Of Groningen

34. *"Developing human cellular phenotypic assays for pain"*
StemBANCC - Satyan Chintawar, University of Oxford

35. *"Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells"*
OncoTrack - Joseph Regan, Charité - Universitätsmedizin Berlin

36. *"A validated genetics-led system 'Pi' enables drug target discovery for immune traits"*
ULTRA-DD - Hai Fang, University Of Oxford

37. *"Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine"*
EBOVAC 1 and 2 - Viki Bockstal, Janssen Vaccines & Prevention

38. *"A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms"*
PERISCOPE - Hans de Graaf, University of Southampton

39. *"Translational Safety Assessment in Pharma"*
eTRANSAFE – Ruud Bueters, Janssen

40. *"In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms"*
iABC - María Díez-Aguilar, Hospital Universitario Ramón y Cajal-IRyCIS

41. *"Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease"*
IMPRIND - Charlotte Delay, Janssen Pharmaceuticals

42. *"Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia"*
EMIF-AD - Olin Jansen, Maastricht University

From concept to trial

43. *"Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data"*
eTOX - Kevin Pinto Gil, University Pompeu Fabra

44. *"Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium"*
HARMONY - Mattia D'Agostino, University of Turin

45. *"Altering disease course before symptom onset: the European Prevention of Alzheimer's Dementia (EPAD) project (WP4)"*
EPAD - Delia Gheorghe, University of Oxford

46. *"COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance"*
COMBACTE-NET - Tomislav Kostyanev, University of Antwerp

47. *"Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)"*
COMBACTE-CARE and COMBACTE-NET - Tomislav Kostyanev, University of Antwerp

48. *"Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort"*
EU-AIMS - Jumana Ahmad, King's College London

49. *"Novel peptide vaccines against Rift valley fever virus"*
ZAPI - Benjamin Gutjahr, Friedrich-Loeffler-Institut FLI

50. *"Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer's Disease across the spectrum"*
ROADMAP - Amanda Ly, University of Edinburgh

51. *"Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder"*
EU-AIMS - Pilar Garces, Roche

52. *"Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso"*
EBOVAC2 - Barry Houreratou, Centre MURAZ

53. *"A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals"*
EQIPD - Jan Vollert, Imperial College London

54. *"A Highly Productive Semi-Automated High Throughput Purification Process"*
ELF - Laura Mariana Levy, Taros

55. *"The Design and Synthesis of Innovative 3D Rich Scaffolds for Screening Libraries"*
ELF - Stanimira Hristeva, Taros

56. *"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study"*
EBOVAC & EBOPLUS - Francesco Santoro, University of Siena

57. *"Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine"*
VSV-EBOVAC - VSV-EBOPLUS - Francesco Santoro, University of Siena

New clinical and regulatory paradigms

58. *"What is responsible antibiotic use? Towards a global definition"*
DRIVE-AB - Annelie Monnier, Radboud University Medical Center & Hasselt University

59. *"The added value of quantitative amyloid PET in determining Alzheimer's Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study"*
AMYPAD - Isadora Lopes Alves, VU Medical Center Amsterdam

60. *"Towards an adaptive mindset"*
ADAPT SMART - Solange Rohou, Astrazeneca

61. *"Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease"*
ROADMAP - Diana O'Rourke, National Institute for Health and Care Excellence (NICE)

62. *"Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited"*
COMBACTE - Jan Feifel, Ulm University

63. *"European Prevention of Alzheimer's Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials"*
EPAD - Lisa Vermunt, VU University Medical Center

64. *"Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals*
iPiE - John Wilkinson, University of York

65. *"Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer's Disease"*
ROADMAP - Marieke Dekker, Medicines Evaluation Board (MEB-CBG)

66. *"IMI-PROTECT and benefit risk assessment"*
PROTECT - Edward Waddingham, Imperial College London

67. *"Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone"*
EBOVAC - Frank Baiden, London School of Hygiene and Tropical Medicine

Patient engagement along the value chain

68. *"Characterising and appraising patient preference exploration and elicitation methods"*
PREFER - Chiara Whichello, Erasmus University Rotterdam

69. *"Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics"*
RESCEU - Joanne G. Wildenbeest , Wilhelmina Children's Hospital, University Medical Center Utrecht

70. *"Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes"*
PARADIGM - Chi Pakarinen, the Synergist

71. *"Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone"*
EBOVAC1 - Shona Lee, EBOVAC Salone, Social Science Team

72. *"Bridging the gap between intention and action - Lessons learned from INNODIA's Patient Advisory Committee"*
INNODIA - Jeannette Soderberg, JDRF